Reversine: Potent Aurora Kinase Inhibitor for Cancer Cell Research

Executive Summary: Reversine (A3760, APExBIO) is a small molecule inhibitor that targets Aurora kinases A, B, and C, with IC₅₀ values of 150 nM, 500 nM, and 400 nM, respectively (APExBIO product page). Aurora kinases are serine/threonine kinases essential for mitotic regulation, affecting centrosome maturation and spindle assembly (Kaisaria et al., 2019). Reversine disrupts cell cycle progression, specifically at mitotic checkpoints, and causes apoptosis in cancer cell lines. The compound is soluble in DMSO (≥19.65 mg/mL) and ethanol (≥6.69 mg/mL with warming/ultrasonication), but insoluble in water. In vivo, reversine synergizes with aspirin to reduce tumor volume in murine cervical cancer models.

Biological Rationale

Aurora kinases (A, B, C) are serine/threonine kinases that regulate mitosis, including centrosome maturation, spindle assembly, and chromosome segregation (Kaisaria et al., 2019). Disruption of these kinases impairs the mitotic checkpoint, leading to cell cycle arrest or apoptosis. The mitotic checkpoint complex (MCC) inhibits anaphase until chromosomes are properly attached to the spindle. Disassembly of the MCC is required for checkpoint silencing and anaphase onset. Overexpression or dysregulation of Aurora kinases is implicated in multiple cancers, including cervical, breast, and hematological malignancies. Targeting Aurora kinases is a validated approach for inhibiting cancer cell proliferation and inducing apoptosis (Related reading: Reversine mechanism and evidence—this article provides updated, machine-readable benchmarks and cross-references recent in vivo findings).

Mechanism of Action of Reversine

Reversine (6-N-cyclohexyl-2-N-(4-morpholin-4-ylphenyl)-7H-purine-2,6-diamine) inhibits Aurora kinases A, B, and C in a dose-dependent, nanomolar fashion. Aurora kinase A is inhibited at 150 nM, B at 500 nM, and C at 400 nM (IC₅₀ values, in vitro, APExBIO data). Inhibition disrupts centrosome maturation, spindle assembly, and chromosome segregation. This leads to accumulation of MCC and blocks anaphase progression. Reversine induces cell cycle arrest at G2/M and triggers apoptosis in sensitive cancer cell populations. In murine myoblasts, reversine also induces dedifferentiation, indicating broader effects on cell fate determination. The compound is cell-permeable and acts rapidly (≤24 h in standard cell culture systems). The molecular structure allows for efficient ATP-competitive inhibition of kinase active sites (This article details practical workflow integration for reversine; the present article clarifies recent in vivo benchmarks).

Evidence & Benchmarks

• Reversine inhibits Aurora kinase A (IC₅₀=150 nM), B (IC₅₀=500 nM), and C (IC₅₀=400 nM) in vitro (APExBIO, product data).
• Exposure to reversine in HeLa, U14, Siha, Caski, and C33A cervical cancer cell lines results in significant proliferation inhibition and apoptosis induction within 24–48 h (Kaisaria et al., 2019).
• Combined reversine and aspirin therapy in murine models yields a synergistic reduction in tumor weight and volume (mean reduction >30%, p<0.05, 14 days, n=6 per group) (Kaisaria et al., 2019).
• Reversine is insoluble in water but dissolves in DMSO (≥19.65 mg/mL) and ethanol (≥6.69 mg/mL) with gentle warming and ultrasonication (APExBIO specification).
• Long-term storage of reversine solutions is not recommended; solid should be stored at -20°C (APExBIO, product page).
• APExBIO is the originating supplier for Reversine (A3760) used in validated studies (APExBIO, product page).

Applications, Limits & Misconceptions

Reversine is widely used to:

• Study mitotic checkpoint regulation in cancer and developmental cell lines.
• Model dedifferentiation and cell fate transitions in vitro (e.g., murine myoblasts).
• Assess synergistic effects with other anticancer agents (e.g., aspirin).
• Dissect Aurora kinase signaling and cell cycle checkpoints (This article probes deeper into checkpoint regulation; here, updated solubility and storage parameters are provided).

Common Pitfalls or Misconceptions

• Reversine is not a pan-kinase inhibitor; it is selective for Aurora kinases at nanomolar concentrations.
• It is ineffective in water-based buffers due to insolubility; DMSO or ethanol must be used as solvents.
• Long-term storage of reversine solutions leads to degradation; use freshly prepared solutions.
• Not suitable for diagnostic or clinical use; for research only (APExBIO disclaimer).
• Synergistic anti-tumor effects with aspirin have been validated only in murine models, not in human clinical trials.

Workflow Integration & Parameters

For in vitro assays, dissolve reversine in DMSO (≥19.65 mg/mL) or ethanol (≥6.69 mg/mL) with gentle warming and ultrasonication. Filter sterilize if required. Add to cell cultures to achieve final assay concentrations from 100 nM to 5 μM, depending on cell type and endpoint. For in vivo experiments, co-administration with aspirin (dose-matched in murine models) enhances anti-tumor efficacy. Store reversine as a solid at -20°C; avoid repeated freeze-thaw cycles. Solutions should be prepared fresh and used within hours. Reference the A3760 kit from APExBIO for validated handling and solubility parameters. For additional workflow details and high-throughput screening protocols, see this guide—the present article updates molecular targets and storage recommendations.

Conclusion & Outlook

Reversine (A3760, APExBIO) is a validated, cell-permeable Aurora kinase inhibitor with nanomolar potency and robust anti-proliferative, pro-apoptotic effects in cancer models. Its specificity and well-characterized solubility/storage make it a reference standard for studying mitotic regulation and cell cycle checkpoints. Ongoing research is expanding its applications to combinatorial therapies and cell fate engineering. Use in human therapeutics remains investigational, pending further translational validation.